Search Medical Condition
Please enter condition
Please choose location

Tumbi Umbi, Australia Clinical Trials

A listing of Tumbi Umbi, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (39) clinical trials

A Phase II Study to Assess the Safety Tolerability and Efficacy of Xanamem in Subjects With Mild Dementia Due to AD (XanADu)

This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem once daily in adult subjects with mild dementia due to AD. Based on Xanamem's mode of action on hippocampal function, amnestic symptoms may respond best, thus favouring the inclusion ...

Phase

0.0 miles

Learn More »

Observational Study of Obstructive Lung Disease (NOVELTY)

The NOVELTY study is a multi-country, multicentre, observational, prospective, longitudinal cohort study which will include patients with a physician diagnosis, or suspected diagnosis, of asthma and/or COPD. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. All patients enrolled in the NOVELTY study ...

Phase N/A

0.0 miles

Learn More »

Performance of Ellume Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Patients With Acute Pharyngitis.

Participants who meet the eligibility criteria and who consent to participation or whose parents/legal guardian consent to their participation, will be enrolled in the study for a period of up to 14 days. Enrolment visit (Day 1) assessments for all participants will include the collection of throat swabs, testing by ...

Phase N/A

0.0 miles

Learn More »

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the ...

Phase

5.93 miles

Learn More »

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will ...

Phase

5.93 miles

Learn More »

An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

This is a randomized (study drug assigned by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), multi-center (more than one hospital or medical school team work on a medical research study), placebo-controlled, parallel-group study in participants who are asymptomatic and at risk for ...

Phase

7.04 miles

Learn More »

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

7.23 miles

Learn More »

Global Non-interventional Heart Failure Disease Registry

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for ...

Phase N/A

7.23 miles

Learn More »

A Study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung Cancer

Patients will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The Co-primary objectives of this study are to assess the efficacy of durvalumab compared to SoC in terms of PFS (Progression Free Survival) and OS (Overall Survival) in patients with NSCLC

Phase

7.23 miles

Learn More »